2018—A Year in Research
This past year, therapeutic antibodies massively reduced brain amyloid, blood tests came into their own, and systems-based approaches transformed the study of gene expression, glial cells, and selective vulnerability.
ALL NEWS
291 RESULTS
Sort By:
- Most Recent
- Most Commented
Brain Conference Spotlights Transcriptomics, Therapeutic Strategies
New potential immunotherapies and insight into single-cell responses were highlights of a small meeting in Denmark.
Rare Luck: Two Copies of ApoE2 Shield Against Alzheimer’s
ApoE2 homozygotes have a dramatically lower risk of AD than even the previously known low-risk E2/3 heterozygotes. More study of this protective allele could reveal roots of resilience.
As DIAN Wraps Up Anti-Aβ Drug Arms, it Sprouts Tau, Primary Prevention Arms
The DIAN Trials Unit is nearing the end of its first two secondary prevention trials. It has begun a cognitive run-in period for its next trial, of a tau-based drug, and for a primary prevention study in people as young as 18.
International Symposium Puts PSP/CBD on the Map
Researchers gain traction in the study of these rare tau disorders, which are sometimes confused with Alzheimer’s disease.
American Academy of Neurology 2019 Annual Meeting
Antisense Oligonucleotides: Can They Take on ALS, SMA, Prions? Drug Reported to Help Alzheimer’s Patients Sleep Better American Academy of Neurology 2019 Annual Meeting ...
Off-Balance Endocytosis Lays Groundwork for Disease
By aging cultured neurons and manipulating them to stimulate endocytosis or interfere with vesicle release, researchers can bring about characteristics of Alzheimer’s—without adding APP or Aβ.
Which Are the Right Tests to Satisfy New FDA Guidance?
The Food and Drug Administration has said it will accept cognition alone as the basis for approval in preclinical AD. Now what? Industry is confronting the challenge to show robust and meaningful change.
Antisense Oligonucleotides: Can They Take on ALS, SMA, Prions?
Data on ASOs, presented recently at the annual meeting of the American Academy of Neurology, depict RNA-based therapies as broadly on the rise in neurodegenerative diseases.
Herpesvirus: Trigger for Many Brain Pathologies?
At Quebec conference, researchers considered multiple aspects of herpesvirus biology that may come in to play in AD.
Can Induced Neurons Identify Early Signs of Neurodegeneration?
In patient-derived neurons, tau mutations scupper lysosomes and SORLA shunts APP through different types of endosomes.
GABA-A Receptor Structures Point to Drug Mechanisms
CryoEM helps explain how the inhibitory receptors open and close their ion channels.
11th ICFTD Meeting in Sydney Sorts Out Clinical Subtypes
Can genetics please parse the confusing spectrum of frontotemporal dementias? Whole genome sequences make a start.
Colombian Cohort Delivers Data on Blood NfL
In 2,144 Colombian ADAD family members, plasma NfL in gene carriers rises as early as two decades before their symptoms start.
Blood Test Granted Breakthrough Status, To Be Tested in Trial
The FDA has prioritized review of C2N’s blood test for amyloid-β. A pivotal clinical trial will correlate the test with amyloid PET scans.
Current Filters
- Date Range : Sep 2018 to Sep 2019 x